The open-label, reduced-design, Phase 1 study evaluating the pharmacokinetics (PK), pharmacodynamics and safety of rusfertide in subjects with severe renal impairment and in subjects with moderate hepatic impairment compared to healthy subjects
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Rusfertide (Primary)
- Indications Renal impairment
- Focus Pharmacodynamics; Pharmacokinetics
- 21 Jan 2025 New trial record